Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
Stereotaxis (NYSE: STXS) announced that Hospital da Luz in Lisbon, Portugal has successfully implemented and treated its first patients using the Genesis Robotic Magnetic Navigation (RMN) System. Hospital da Luz Lisboa, part of Portugal's largest health group Luz Saude, is a university hospital that has performed over 4,000 robotic cardiac ablation procedures. The Genesis System represents the latest advancement in Robotic Magnetic Navigation technology, designed to treat arrhythmias through minimally invasive cardiac ablation procedures with robotic precision and safety.
Stereotaxis (NYSE: STXS) ha annunciato che l'Hospital da Luz di Lisbona, Portogallo, ha implementato con successo e trattato i suoi primi pazienti utilizzando il Genesis Robotic Magnetic Navigation (RMN) System. L'Hospital da Luz Lisboa, parte del più grande gruppo sanitario del Portogallo, Luz Saude, è un ospedale universitario che ha eseguito oltre 4.000 procedure di ablazione cardiaca robotica. Il sistema Genesis rappresenta l'ultima evoluzione nella tecnologia di Navigazione Magnetica Robotica, progettato per trattare le aritmie attraverso procedure di ablazione cardiaca minimamente invasive con precisione e sicurezza robotiche.
Stereotaxis (NYSE: STXS) anunció que el Hospital da Luz en Lisboa, Portugal, ha implementado con éxito y tratado a sus primeros pacientes utilizando el Genesis Robotic Magnetic Navigation (RMN) System. El Hospital da Luz Lisboa, parte del grupo de salud más grande de Portugal, Luz Saude, es un hospital universitario que ha realizado más de 4,000 procedimientos de ablación cardíaca robótica. El sistema Genesis representa el último avance en la tecnología de Navegación Magnética Robótica, diseñado para tratar arritmias a través de procedimientos de ablación cardíaca mínimamente invasivos con precisión y seguridad robótica.
스테레오택시스 (NYSE: STXS)는 포르투갈 리스본의 Hospital da Luz가 제네시스 로보틱 자석 내비게이션 (RMN) 시스템을 사용하여 첫 번째 환자 치료를 성공적으로 수행했다고 발표했습니다. 포르투갈 최대 의료 그룹인 Luz Saude에 속한 Hospital da Luz Lisboa는 4,000건 이상의 로봇 심장 절제술을 시행한 대학 병원입니다. 제네시스 시스템은 로봇 정밀성과 안전성을 갖춘 최소한의 침습적 심장 절제술로 부정맥을 치료하기 위해 설계된 로봇 자석 내비게이션 기술의 최신 발전을 나타냅니다.
Stereotaxis (NYSE: STXS) a annoncé que l'Hôpital da Luz à Lisbonne, Portugal, a mis en œuvre avec succès et traité ses premiers patients en utilisant le Système de Navigation Magnétique Robotique Genesis (RMN). L'Hôpital da Luz Lisboa, faisant partie du plus grand groupe de santé du Portugal, Luz Saude, est un hôpital universitaire qui a effectué plus de 4 000 procédures d'ablation cardiaque robotique. Le Système Genesis représente la dernière avancée dans la technologie de Navigation Magnétique Robotique, conçu pour traiter les arythmies par des procédures d'ablation cardiaque minimales invasives avec une précision et une sécurité robotiques.
Stereotaxis (NYSE: STXS) gab bekannt, dass das Hospital da Luz in Lissabon, Portugal, erfolgreich seine ersten Patienten mit dem Genesis Robotischem Magnetnavigationssystem (RMN) behandelt hat. Das Hospital da Luz Lisboa, Teil der größten Gesundheitsgruppe Portugals, Luz Saude, ist ein Universitätsklinikum, das über 4.000 robotergestützte Herzablationen durchgeführt hat. Das Genesis-System stellt den neuesten Fortschritt in der Technologie der robotischen Magnetnavigation dar, die entwickelt wurde, um Arrhythmien durch minimal-invasive Herzablationen mit robotischer Präzision und Sicherheit zu behandeln.
- First successful implementation of Genesis RMN System in Portugal
- Partnership with major healthcare institution (largest health group in Portugal)
- Hospital's track record of over 4,000 robotic cardiac ablation procedures demonstrates strong adoption
- None.
Insights
The adoption of the Genesis Robotic System by Hospital da Luz represents a modest positive development for Stereotaxis, though its immediate financial impact is likely The installation expands the company's European footprint and validates its technology in a new market. Hospital da Luz's track record of over 4,000 robotic cardiac ablation procedures suggests strong potential utilization rates.
The strategic value lies in establishing a reference site in Portugal, which could drive additional adoptions in the region. However, single-system installations typically generate $1-2 million in upfront revenue, with recurring revenue from disposables tied to procedure volumes. While positive for market expansion, this development alone is unlikely to materially impact Stereotaxis's near-term financial performance given its
ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.
“We are excited to be at the forefront of technology and patient care by introducing the new Genesis System at Hospital da Luz,” said Prof. Pedro Adragão, Cardiac Electrophysiologist at Hospital da Luz. “Robotics allows us to treat patients with effective individualized therapy and the highest focus on safety. We are pleased to offer this high-level care to all our patients, including those with the most complex arrhythmia. We also are pleased to continue advancing this important technology for the benefit of patients and medical progress.”
Hospital da Luz Lisboa is a University Hospital affiliated with the Luz Saude group, the largest health group in Portugal. The hospital is a global leader in diagnosing and treating complex heart conditions, having performed over 4,000 robotic cardiac ablation procedures. The Genesis System is the latest advancement in Robotic Magnetic Navigation technology. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“We are delighted to expand our long-term relationship with Prof. Adragão and Hospital da Luz,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to supporting their efforts to improve patient care, advance clinical science, and pioneer robotic innovation.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is the first hospital in Portugal to implement Stereotaxis (STXS) Genesis Robotic System?
How many robotic cardiac ablation procedures has Hospital da Luz performed with Stereotaxis (STXS) technology?
What medical conditions does the Stereotaxis (STXS) Genesis System treat?
